ReviewBritish journal of cancer2023
Checkpoint inhibitors and anti-angiogenic agents: a winning combination.
Review in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Three-Year Follow-Up of the Phase II Trial for Resectable Non-Small-Cell Lung Cancer Treated With Perioperative Sintilimab and Neoadjuvant Anlotinib Plus Chemotherapy: TD-NeoFOUR Trial.Thoracic cancer · 2025Trial
- Trial
- Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial.British journal of cancer · 2024Trial
- Combined Anti-PD-1/PD-L1 and Anti-angiogenic Therapy: An Emerging Direction for Future NSCLC Treatment.Current treatment options in oncology · 2026Review
- Vessels encapsulating tumor clusters is associated with impaired efficacy of adjuvant immunotherapy in resected hepatocellular carcinoma.Journal of advanced research · 2026Article
- Targeting the cancer metabolism-immunity interface: update and perspectives.Experimental hematology & oncology · 2026Review
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
- Gastric cancer cells-derived exosomal miR-151a-5p induces an immunosuppressive microenvironment through promoting LAG3Journal of experimental & clinical cancer research : CR · 2026Article
- [Heterogeneity of Response to PD-1/PD-L1 Inhibitors in Elderly Patients with Advanced NSCLC under the Background of Immunosenescence and Intervention Strategies].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Article
- Vaccination against tumour endothelial marker Robo4 inhibits tumour growth.Immunotherapy advances · 2026Article
- Research Advances in the Endometriotic Microenvironment: Synergistic Immune-Inflammatory-Angiogenic Interactions and their Therapeutic Translation.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- Tumor immune-vascular crosstalk: synergy and translation of immune checkpoint inhibitors and anti-angiogenic agents in melanoma.Frontiers in immunology · 2026Review
- Drug resistance mechanisms of immunotherapy and translational strategies for reversing resistance for hepatocellular carcinoma: from bench to bedside.Frontiers in immunology · 2026Review
- Clinical-radiomics nomogram integrating lymph node radiomic features to predict immunotherapy response in advanced biliary tract cancers.Journal for immunotherapy of cancer · 2025Article
- Immune Checkpoint Therapy for Thymic Carcinoma.Cancers · 2025Review
- Combination of racotumomab immunotherapy with programmed death-1 blockade in a preclinical model of non-small cell lung cancer.Translational lung cancer research · 2025Article
- Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective.Clinical and experimental medicine · 2025Review
- Clofazimine enhances anti-PD-1 immunotherapy in glioblastoma by inhibiting Wnt6 signaling and modulating the tumor immune microenvironment.Cancer immunology, immunotherapy : CII · 2025Article
- Advances in immuno-based and targeted therapies in extensive-stage small cell lung cancer.Therapeutic advances in medical oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The combination of immune checkpoint inhibitors and anti-angiogenic agents is a promising new approach in cancer treatment. Immune checkpoint inhibitors block the signals that help cancer cells evade the immune system, while anti-angiogenic agents target the blood vessels that supply the tumour with nutrients and oxygen, limiting its growth. Importantly, this combination triggers synergistic effects based on molecular and cellular mechanisms, leading to better response rates and longer progression-free survival than treatment alone. However, these combinations can also lead to increased side effects and require close monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.